Drugs / SCIB1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01138410 | May 2010 → Jul 2017 | melanoma | Scancell Ltd | Terminated | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04079166 | Aug 2019 → Jan 2027 expected | cutaneous melanoma | Scancell Ltd | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-12-09 | Scancell Ltd | Results Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ scancell.co.uk ↗
Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1 |
| 2025-07-22 | Scancell Ltd | Results Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody ® iSCIB1+ scancell.co.uk ↗ |
| 2025-04-01 | Scancell Ltd | Results Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting scancell.co.uk ↗
Initial data in 25 patients has shown • 84% disease control rate; • 80% progression free survival, with 20% complete response rate; and • 72% objective response rate. |
| 2025-02-17 | Scancell Ltd | Results Scancell to present translational data from the Phase 2 ongoing SCOPE trial of SCIB1 at the 2025 AACR IO conference scancell.co.uk ↗
The translational data that will be presented demonstrates functional vaccine specific T cell responses for patients enrolled in cohort 1 (SCIB1 plus ipilimumab and nivolumab). |
| 2024-11-18 | Scancell Ltd | Results Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma scancell.co.uk ↗
These patients are showing progression free survival (PFS) of 80% at 6 months, with 5 (20%) complete responders (CR). |
| 2023-11-28 | Scancell Ltd | Results Update on SCOPE trial scancell.co.uk ↗
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces today it has two further responders on the SCOPE study, bringing the number of responders to 11 out of 13 patients. |
| 2023-11-10 | Scancell Ltd | Results Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research scancell.co.uk ↗
Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research |
| 2023-09-19 | Scancell Ltd | Results Scancell announces positive data from the first stage in its Phase 2 SCOPE trial with SCIB1 cancer vaccine delivered by needle free injection for advanced melanoma scancell.co.uk ↗ |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCIB1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01138410 ↗ |
| Modality | Vaccine | “SCIB1 or iSCIB1+ DNA vaccine” NCT04079166 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT01138410 ↗ |